Stimulation of an anti-tumor immune response with “chromatin-damaging” therapy | SpringerLink
APExBIO - CBL0137 (hydrochloride) | curaxin that activates p53 and inhibits NF-κB | CAS# 1197397-89-9
FACT Complex-targeting Curaxin CBL0137 for Refractory Lymphomas Clinical Trial | Power
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137 | Cell Death & Disease
CBL0137 overcomes developmental signals that drive neuroblast... | Download Scientific Diagram
The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma - ScienceDirect
The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma - ScienceDirect
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137 | Cell Death & Disease
Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG - ScienceDirect
The anti-cancer drugs curaxins target spatial genome organization | Nature Communications
APExBIO - CBL0137 | curaxin that activates p53 and inhibits NF-κB | CAS# 1197996-80-7
Anticancer Drug Cbl0137 Highly Effective Against Infant Leukaemia | CCI
CBL0137 inhibits EPC in vitro. a A 13-nucleosome 601207 × 13 array for... | Download Scientific Diagram
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pan
Potent antileukemic activity of curaxin CBL0137 against MLL‐rearranged leukemia - Somers - 2020 - International Journal of Cancer - Wiley Online Library
Frontiers | The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression | Oncology
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pan
CBL0137 | ≥99%(HPLC) | Selleck | NF-κB inhibitor
The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma - ScienceDirect
The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma - ScienceDirect
Potent antileukemic activity of curaxin CBL0137 against MLL‐rearranged leukemia - Somers - 2020 - International Journal of Cancer - Wiley Online Library
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137 | Cell Death & Disease
IJMS | Free Full-Text | Exploring the Interaction of Curaxin CBL0137 with G-Quadruplex DNA Oligomers | HTML
Frontiers | Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms | Oncology
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pan
Australian Researchers Find New Way to Target Deadly Childhood Cancer With CBL0137 | The Cure Starts Now
